Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Non-Current Assets (2021 - 2026)

TriSalus Life Sciences has reported Non-Current Assets over the past 6 years, most recently at $2.8 million for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 19.5% year-over-year to $2.8 million; the TTM value through Mar 2026 reached $12.3 million, down 17.97%, while the annual FY2025 figure was $3.1 million, 6.51% down from the prior year.
  • Non-Current Assets for Q1 2026 was $2.8 million at TriSalus Life Sciences, down from $3.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $251.0 million in Q3 2022 and troughed at $2.8 million in Q1 2026.
  • A 5-year average of $48.7 million and a median of $4.5 million in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: tumbled 98.2% in 2023 and later dropped 6.51% in 2025.
  • Year by year, Non-Current Assets stood at $4.8 million in 2022, then fell by 21.86% to $3.7 million in 2023, then decreased by 11.62% to $3.3 million in 2024, then fell by 6.51% to $3.1 million in 2025, then dropped by 7.97% to $2.8 million in 2026.
  • Business Quant data shows Non-Current Assets for TLSI at $2.8 million in Q1 2026, $3.1 million in Q4 2025, and $3.1 million in Q3 2025.